01 November 2021>: Human Study
Prevalence of Hepatitis B and C Virus Infections: Influence of National Health Care Policies and Local Clinical Practices
Veeravan Lekskulchai ACDEF*DOI: 10.12659/MSMBR.933692
Med Sci Monit Basic Res 2021; 27:e933692
Table 2 Utilization of the tests for hepatitis B surface antigen (HBsAg) and anti-hepatitis C virus antibody (anti-HCV Ab).*
Sex/age | Year | Total | ||
---|---|---|---|---|
2016 | 2017 | 2018 | ||
Test for HBsAg | ||||
Male, N (%) | 1327 (29) | 1251 (27) | 1035 (27) | 3613 (28) |
Age range, y | 1–92 | 1–94 | 1–95 | 1–95 |
Age, mean (SD) | 50.96 (17.35) | 50.21 (17.43) | 49.16 (19.10) | 50.18 (17.90) |
Female, N (%) | 3192 (71) | 3398 (73) | 2731 (73) | 9321 (72) |
Age range, y | 1–95 | 1–96 | 1–97 | 1–97 |
Age, mean (SD) | 39.72 (17.35) | 38.37 (16.66) | 37.95 (16.96) | 38.71 (16.79) |
Test for anti-HCV Ab | ||||
Male, N (%) | 794 (56) | 856 (52) | 853 (52) | 2503 (53) |
Age range, y | 2–92 | 2–94 | 1–95 | 1–95 |
Age, mean (SD) | 52.75 (18.15) | 52.50 (17.32) | 52.24 (18.29) | 52.49 (17.91) |
Female, N (%) | 635 (44) | 802 (48) | 785 (48) | 2222 (47) |
Age range, y | 1–95 | 1–96 | 1–97 | 1–97 |
Age, mean (SD) | 50.75 (19.89) | 50.68 (19.44) | 51.05 (19.65) | 50.83 (19.64) |
* Counting each case once at the first year of admission during 2016 to 2018. |